Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease

Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of RO4602522 Added To Background Alzheimer's Disease Therapy In Patients With Moderate Severity Alzheimer's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sembragiline (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms MAyflOwer-RoAD
  • Sponsors Roche

Most Recent Events

  • 11 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
  • 30 Jun 2015 Primary endpoint 'Change in Alzheimers Disease Assessment Scale - Cognitive Behaviour Subscale (ADAS-Cog-11) score' has not been met, according to an Evotec AG media release.
  • 14 Mar 2015 According to an Evotec media release, results from this trial are expected in the first half of 2015.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top